{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T12:57:29Z","timestamp":1773925049561,"version":"3.50.1"},"reference-count":24,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2015,1,1]],"date-time":"2015-01-01T00:00:00Z","timestamp":1420070400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,11,5]],"date-time":"2019-11-05T00:00:00Z","timestamp":1572912000000},"content-version":"vor","delay-in-days":1769,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2015,1]]},"DOI":"10.1093\/annonc\/mdu496","type":"journal-article","created":{"date-parts":[[2014,11,22]],"date-time":"2014-11-22T05:34:34Z","timestamp":1416634474000},"page":"149-156","source":"Crossref","is-referenced-by-count":91,"title":["Docetaxel plus oxaliplatin with or without fluorouracil or capecitabine in metastatic or locally recurrent gastric cancer: a randomized phase II study"],"prefix":"10.1016","volume":"26","author":[{"given":"E.","family":"Van Cutsem","sequence":"first","affiliation":[]},{"given":"C.","family":"Boni","sequence":"additional","affiliation":[]},{"given":"J.","family":"Tabernero","sequence":"additional","affiliation":[]},{"given":"B.","family":"Massuti","sequence":"additional","affiliation":[]},{"given":"G.","family":"Middleton","sequence":"additional","affiliation":[]},{"given":"F.","family":"Dane","sequence":"additional","affiliation":[]},{"given":"P.","family":"Reichardt","sequence":"additional","affiliation":[]},{"given":"F.L.","family":"Pimentel","sequence":"additional","affiliation":[]},{"given":"A.","family":"Cohn","sequence":"additional","affiliation":[]},{"given":"P.","family":"Follana","sequence":"additional","affiliation":[]},{"given":"M.","family":"Clemens","sequence":"additional","affiliation":[]},{"given":"A.","family":"Zaniboni","sequence":"additional","affiliation":[]},{"given":"V.","family":"Moiseyenko","sequence":"additional","affiliation":[]},{"given":"M.","family":"Harrison","sequence":"additional","affiliation":[]},{"given":"D.A.","family":"Richards","sequence":"additional","affiliation":[]},{"given":"H.","family":"Prenen","sequence":"additional","affiliation":[]},{"given":"S.","family":"Pernot","sequence":"additional","affiliation":[]},{"given":"E.","family":"Ecstein-Fraisse","sequence":"additional","affiliation":[]},{"given":"S.","family":"Hitier","sequence":"additional","affiliation":[]},{"given":"P.","family":"Rougier","sequence":"additional","affiliation":[]}],"member":"78","reference":[{"key":"10.1093\/annonc\/mdu496_bb0010","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/j.ctrv.2010.01.005","article-title":"Advanced gastric cancer\u2013slow but steady progress","volume":"36","author":"Power","year":"2010","journal-title":"Cancer Treat Rev"},{"key":"10.1093\/annonc\/mdu496_bb0015","first-page":"CD004064","article-title":"Chemotherapy for advanced gastric cancer","volume":"3","author":"Wagner","year":"2010","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1093\/annonc\/mdu496_bb0020","doi-asserted-by":"crossref","first-page":"3813","DOI":"10.1002\/1097-0142(19930615)71:12<3813::AID-CNCR2820711205>3.0.CO;2-5","article-title":"A phase III randomized study of 5-fluorouracil and cisplatin versus 5-fluorouracil, doxorubicin, and mitomycin C versus 5-fluorouracil alone in the treatment of advanced gastric cancer","volume":"71","author":"Kim","year":"1993","journal-title":"Cancer"},{"key":"10.1093\/annonc\/mdu496_bb0025","doi-asserted-by":"crossref","first-page":"2648","DOI":"10.1200\/JCO.2000.18.14.2648","volume":"18","author":"Vanhoefer","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdu496_bb0030","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1200\/JCO.2003.04.130","article-title":"Randomized phase III trial of fluorouracil alone versus fluorouracil plus cisplatin versus uracil and tegafur plus mitomycin in patients with unresectable, advanced gastric cancer: the Japan Clinical Oncology Group Study (JCOG9205)","volume":"21","author":"Ohtsu","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdu496_bb0035","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1200\/JCO.1997.15.1.261","article-title":"Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer","volume":"15","author":"Webb","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdu496_bb0040","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/sj.bjc.6690350","article-title":"Long-term survival after epirubicin, cisplatin and fluorouracil for gastric cancer: results of a randomized trial","volume":"80","author":"Waters","year":"1999","journal-title":"Br J Cancer"},{"key":"10.1093\/annonc\/mdu496_bb0045","doi-asserted-by":"crossref","first-page":"1996","DOI":"10.1200\/JCO.2002.08.105","article-title":"Prospective randomized trial comparing mitomycin, cisplatin, and protracted venous-infusion fluorouracil (PVI 5-FU) with epirubicin, cisplatin, and PVI 5-FU in advanced esophagogastric cancer","volume":"20","author":"Ross","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdu496_bb0050","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1056\/NEJMoa073149","article-title":"Capecitabine and oxaliplatin for advanced esophagogastric cancer","volume":"358","author":"Cunningham","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdu496_bb0055","doi-asserted-by":"crossref","first-page":"4991","DOI":"10.1200\/JCO.2006.06.8429","article-title":"Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group","volume":"24","author":"Van Cutsem","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdu496_bb0060","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1159\/000330199","article-title":"Docetaxel plus oxaliplatin in combination with capecitabine as first-line treatment for advanced gastric cancer","volume":"80","author":"Amarantidis","year":"2011","journal-title":"Oncology"},{"key":"10.1093\/annonc\/mdu496_bb0065","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1007\/s00280-009-0938-4","article-title":"Oxaliplatin, irinotecan, and fluorouracil\/folinic acid in advanced gastric cancer: a multicenter phase II trial of the Southern Italy Cooperative Oncology Group","volume":"64","author":"Comella","year":"2009","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1093\/annonc\/mdu496_bb0070","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/1756-9966-28-34","article-title":"Phase II study of epirubicin, oxaliplatin and docetaxel combination in metastatic gastric or gastroesophageal junction adenocarcinoma","volume":"28","author":"Di Lauro","year":"2009","journal-title":"J Exp Clin Cancer Res"},{"key":"10.1093\/annonc\/mdu496_bb0075","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1159\/000328746","article-title":"A phase II multi-center study of triple therapy with paclitaxel, S-1 and cisplatin in patients with advanced gastric cancer","volume":"80","author":"Iwase","year":"2011","journal-title":"Oncology"},{"key":"10.1093\/annonc\/mdu496_bb0080","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1007\/s00280-011-1701-1","article-title":"A multicenter phase II study of combined chemotherapy with docetaxel, cisplatin, and S-1 in patients with unresectable or recurrent gastric cancer (KDOG 0601)","volume":"69","author":"Koizumi","year":"2012","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1093\/annonc\/mdu496_bb0085","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1007\/s00280-010-1353-6","article-title":"Multicenter phase II trial of S-1, paclitaxel and cisplatin triplet combination chemotherapy in patients with advanced gastric cancer","volume":"67","author":"Kim","year":"2011","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1093\/annonc\/mdu496_bb0090","doi-asserted-by":"crossref","first-page":"3205","DOI":"10.1200\/JCO.2006.10.4968","article-title":"Clinical benefit with docetaxel plus fluorouracil and cisplatin compared with cisplatin and fluorouracil in a phase III trial of advanced gastric or gastroesophageal cancer adenocarcinoma: the V-325 Study Group","volume":"25","author":"Ajani","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdu496_bb0095","doi-asserted-by":"crossref","first-page":"3210","DOI":"10.1200\/JCO.2006.08.3956","article-title":"Quality of life with docetaxel plus cisplatin and fluorouracil compared with cisplatin and fluorouracil from a phase III trial for advanced gastric or gastroesophageal adenocarcinoma: the V-325 Study Group","volume":"25","author":"Ajani","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdu496_bb0100","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.1093\/annonc\/mdn403","article-title":"Biweekly fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) for patients with metastatic adenocarcinoma of the stomach or esophagogastric junction: a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie","volume":"19","author":"Al-Batran","year":"2008","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdu496_bb0105","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1093\/annonc\/mdm269","article-title":"Split-dose docetaxel, cisplatin and leucovorin\/fluorouracil as first-line therapy in advanced gastric cancer and adenocarcinoma of the gastroesophageal junction: results of a phase II trial","volume":"18","author":"Lorenzen","year":"2007","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdu496_bb0110","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/s10120-013-0297-z","article-title":"Optimal chemotherapy for advanced gastric cancer: is there a global consensus?","volume":"17","author":"Lordick","year":"2014","journal-title":"Gastric Cancer"},{"key":"10.1093\/annonc\/mdu496_bb0115","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1093\/annonc\/mdm449","article-title":"Phase II trial of docetaxel and oxaliplatin in patients with advanced gastric cancer and\/or adenocarcinoma of the gastroesophageal junction","volume":"19","author":"Richards","year":"2008","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdu496_bb0120","unstructured":"National Cancer Institute 2012. Surveillance epidemiology and end results. http:\/\/seer.cancer.gov\/statfacts\/html\/stomach.html (22 November 2013, date last accessed)."},{"key":"10.1093\/annonc\/mdu496_bb0125","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/j.ejca.2012.09.025","article-title":"The feasibility of triple-drug chemotherapy combination in older adult patients with oesophagogastric cancer: a randomised trial of the Arbeitsgemeinschaft Internistische Onkologie (FLOT65+)","volume":"49","author":"Al-Batran","year":"2013","journal-title":"Eur J Cancer"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419313365?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419313365?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,6,24]],"date-time":"2021-06-24T07:39:50Z","timestamp":1624520390000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419313365"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,1]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,1]]}},"alternative-id":["S0923753419313365"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mdu496","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2015,1]]}}}